Mümüşoğlu, SezcanAta, BarışTuran, VolkanDemir, BerfuKahyaoğlu, İnciAta, Ayşe SeyhanYılmaz, BülentYakın, KayhanBozdağ, Gürkan2023-02-282023-02-282017-04-08Mümüşoğlu, S. vd. (2017). ''Does pituitary suppression affect live birth rate in women with congenital hypogonadotrophic hypogonadism undergoing intra-cytoplasmic sperm injection? A multicenter cohort study''. Gynecological Endocrinology, 33(9), 728-732.0951-3590https://doi.org/10.1080/09513590.2017.1318278https://www.tandfonline.com/doi/full/10.1080/09513590.2017.13182781473-0766http://hdl.handle.net/11452/31234In this retrospective multicenter cohort study, women with congenital hypogonadotrophic hypogonadism (CHH) (n = 57) who underwent intra-cytoplasmic sperm injection in-between 2010-2014 were compared to age-matched controls with tubal factor infertility (n = 114) to assess ovarian stimulation cycle and pregnancy outcomes. Live birth rates (LBRs) per started cycle were 31.6 and 24.6% in CHH and controls groups, respectively (p = 0.36). Comparable success rates were also confirmed with the logistic regression analysis (OR: 1.44, 95% CI: 0.78-2.67, p = 0.24). Of the 57 women with CHH, 19 were stimulated with the gonadotropin-releasing hormone (GnRH) antagonist protocol, 13 with the long-GnRH-agonist protocol. Pituitary suppression (PS) was not employed in the remaining 25 cases. Compared to women with PS, women without PS had significantly higher embryo implantation rates (21.6 versus 52.6%, p = 0.03). Although there was a trend favoring no PS, LBRs (25.0 versus 40.0%, p = 0.26) per cycle were short of statistical significance. LBRs per cycle (57.1 versus 31.2%, p = 0.11) and miscarriage rates (11.1 versus 16.7%, p = 0.75) were similar between CHH women who were given estrogen + progesterone and progesterone alone to support the luteal phase. In conclusion, the optimal stimulation protocol appears to be exogenous gonadotropin stimulation alone, without PS, and progesterone-only luteal phase support in CHH patients.eninfo:eu-repo/semantics/closedAccessEndocrinology & metabolismObstetrics & gynecologyCongenital hypogonadotrophic hypogonadismControlled ovarian stimulationGnRH AG/ANTAGLuteal supportPituitary suppressionAdultBirth rateCohort studiesEmbryo transferFemaleFertility agents, femaleGonadotropin-releasing hormoneHumansHypogonadismInfertility, femaleLive birthOvulation inductionPregnancySperm injections, intracytoplasmicTreatment outcomeYoung adultArticle0004137076000162-s2.0-8501817347672873233928447505Endocrinology & metabolismObstetrics & gynecologyHuman Menopausal Gonadotropin; In Vitro Fertilization; Ovary HyperstimulationCetrorelixEstradiolEstrogenFollitropinGanirelixHuman menopausal gonadotropinLeuprorelinLuteinizing hormoneRecombinant follitropinRecombinant luteinizing hormoneCetrorelixFertility promoting agentGonadorelinProgesteroneAdultAntral follicle countArticleBirth rateBlastocystCohort analysisCombination drug therapyControlled studyEmbryo (anatomy)Embryo transferEstradiol blood levelFemaleFemale infertilityFertilizationFollitropin blood levelHormonal therapyHumanHypogonadotropic hypogonadismHypophysis functionInborn error of metabolismIntracytoplasmic sperm injectionLive birthLuteal phaseLuteinizing hormone blood levelMajor clinical studyMetaphaseMulticenter studyMidationOocyteOocyte cleavageOocyte maturationOocyte retrievalOvarian reserveOvary cyclePituitary suppressionPregnancy outcomePregnancy ratePriority journalRetrospective studySpontaneous abortionStimulationTreatment outcomeTubal factor infertilityAnalogs and derivativesClinical trialFemale infertilityHypogonadismOvulation inductionPregnancyProceduresYoung adult